Chikungunya virus Senegal strain 37997 envelope protein E2

Star0

DB21768ApprovedInvestigationalVaccines

One of three components of a recombinant Chikungunya virus vaccine called Vimkunya.

Primary indication: Vimkunya is a vaccine indicated for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older.Curator reviewed · 1 structured indication
First approval: United States, 2025 · European Union, 2025
Brand names: Vimkunya

Resolves to

Compound

UNIIYS6E2GD8XA

Clinical / RWD

RxNorm2707122

What you can answer from here — as of August 10, 2026

2Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

2Marketed productsAcross 2 countries and 1 labeller

1+ReferenceStructured and connected to the statements they support

Which other approved drugs treat the same conditions as Chikungunya virus Senegal strain 37997 envelope protein E2, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account